- Home
- FCEL vs CRDL Comparison
FCEL vs CRDL Comparison
Compare FCEL & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCEL
- CRDL
- Stock Information
- Founded
- FCEL 1969
- CRDL 2017
- Country
- FCEL United States
- CRDL Canada
- Employees
- FCEL N/A
- CRDL N/A
- Industry
- FCEL Industrial Machinery/Components
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FCEL Energy
- CRDL Health Care
- Exchange
- FCEL Nasdaq
- CRDL Nasdaq
- Market Cap
- FCEL 130.8M
- CRDL 112.4M
- IPO Year
- FCEL 1992
- CRDL N/A
- Fundamental
- Price
- FCEL $5.62
- CRDL $1.44
- Analyst Decision
- FCEL Hold
- CRDL Strong Buy
- Analyst Count
- FCEL 6
- CRDL 2
- Target Price
- FCEL $14.11
- CRDL $9.00
- AVG Volume (30 Days)
- FCEL 2.4M
- CRDL 289.4K
- Earning Date
- FCEL 09-04-2025
- CRDL 08-11-2025
- Dividend Yield
- FCEL N/A
- CRDL N/A
- EPS Growth
- FCEL N/A
- CRDL N/A
- EPS
- FCEL N/A
- CRDL N/A
- Revenue
- FCEL $129,424,000.00
- CRDL N/A
- Revenue This Year
- FCEL $40.32
- CRDL N/A
- Revenue Next Year
- FCEL $36.17
- CRDL N/A
- P/E Ratio
- FCEL N/A
- CRDL N/A
- Revenue Growth
- FCEL 48.62
- CRDL N/A
- 52 Week Low
- FCEL $3.58
- CRDL $0.77
- 52 Week High
- FCEL $16.65
- CRDL $2.63
- Technical
- Relative Strength Index (RSI)
- FCEL 51.89
- CRDL 56.90
- Support Level
- FCEL $5.30
- CRDL $1.14
- Resistance Level
- FCEL $6.31
- CRDL $1.42
- Average True Range (ATR)
- FCEL 0.38
- CRDL 0.10
- MACD
- FCEL 0.04
- CRDL 0.01
- Stochastic Oscillator
- FCEL 53.95
- CRDL 83.33
About FCEL FuelCell Energy Inc.
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products and electrolysis platforms that decarbonize power and produce hydrogen. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company operates in USA, South Korea, Europe and Canada. Majority of revenue is from USA and South Korea.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.